

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
29 July 2004 (29.07.2004)

PCT

(10) International Publication Number  
**WO 2004/062651 A1**

(51) International Patent Classification<sup>7</sup>: A61K 9/72, 39/39

(21) International Application Number:

PCT/GB2004/000104

(22) International Filing Date: 14 January 2004 (14.01.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0300885.1 15 January 2003 (15.01.2003) GB

(71) Applicant (for all designated States except US): **THE SECRETARY OF STATE FOR DEFENCE** [GB/GB]; DSTL, Porton Down, Salisbury, Wiltshire SP4 0JQ (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **EYLES, James, Edward** [GB/GB]; DSTL, Porton Down, Salisbury, Wiltshire SP4 0JQ (GB). **PHILLIPS, Gary, John** [GB/GB]; DSTL, Porton Down, Salisbury, Wiltshire SP4 0JQ (GB). **MAIDMENT, Michael, Patrick** [GB/GB]; DSTL, Porton Down, Salisbury, Wiltshire SP4 0JQ (GB). **WILLIAMSON, Ethel, Diane** [GB/GB]; DSTL, Porton Down, Salisbury, Wiltshire SP4 0JQ (GB).

(74) Agents: **GREAVES, Carol, Pauline et al.**; Greaves Brewster, Indigo House, Cheddar Business Park, Wedmore Road, Cheddar BS27 3EB (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL AEROSOL COMPOSITION

(57) Abstract: An aerosol formulation comprising a biodegradable microsphere comprising a non-living reagent, such as a sub-unit vaccine, that produces a protective immune response in a mammal to whom it is administered. Nebulizers and inhalers containing such formulations are also described and claimed.

**BEST AVAILABLE COPY**



**WO 2004/062651 A1**

**THIS PAGE BLANK (USPTO)**

## PHARMACEUTICAL AEROSOL COMPOSITION

The present invention relates to pharmaceutical compositions,  
and in particular to compositions comprising immunogens, used in  
5 the prophylactic and therapeutic treatment of infections.

The option to self administer vaccines by inhalation, for  
example using a nebulizer or inhaler such as a dry powder  
inhaler, would be advantageous from a logistical standpoint and  
10 may be particularly effective for protecting individuals from  
pathogens that affect or utilise the respiratory tract as a  
portal of entry into the body.

US Patent No. 6,428,771 describes a method for controlled drug  
15 delivery to the pulmonary system using microparticles  
incorporating the drug. Particles are described as having a  
diameter of from 0.5 and 10 $\mu$ m. It is suggested that the drug may  
in fact comprise an antigen intended to elicit an a protective  
immune response. However this is not demonstrated.

20 Furthermore, administration of in particular non-living  
vaccines, such as sub-unit vaccines, has not yet been found to  
give effective protection using this mode of administration (see  
for example C.W. Purdy et al., Current Microbiology, (1998), 37,  
25 p5).

The applicants have found that biodegradable microspheres,  
containing antigen, can engender immunological responses  
following delivery to experimental animals in the form of an  
30 aerosol, provided the microspheres are of a type which are  
delivered most efficiently to the lung.

According to the present invention there is provided an aerosol  
formulation comprising a biodegradable microsphere of average  
35 diameter of from 0.5 to 5 $\mu$ m and comprising a non-living reagent

that produces a protective immune response in a host mammal to whom it is administered.

As used herein, the term "non-living reagent" refers to immunogens such as polypeptides or proteins, which are derived for example from a pathogen such as a bacteria, virus or fungi. It also refers to inactivated microorganisms such as heat or chemically killed bacteria and/or viruses.

The term "aerosol" refers to a formulation that is deliverable in the form of a dispersion of a solid and/or liquid in a gas. These may be prepared from suspensions of the formulation in a liquid such as water, using a device such as a nebulizer, or from dry powders using a dry powder inhaler. In the case of the nebulized aerosol, the dispersion comprises essentially wet microspheres in air.

The term "average diameter " as used herein, refers to the mean mass aerodynamic diameter of the microspheres. Mean mass aerodynamic diameter is a measurement of particle size in an aerosol, which is the most relevant measurement when trying to predict if particles are respirable.

These formulations are effective in the administration of reagents, which are capable of generating a protective immune response in an animal, particularly a mammal, to which it is administered. Examples of such agents include antigenic polypeptides as well as nucleic acid sequences which may encode these polypeptides and which are known as "DNA" vaccines.

Suitable polypeptides are sub-unit vaccines and others, such as diphtheria toxoid, tetanus toxoid, *Botulinum* toxin FHC and *Bacillus anthracis* protective antigen (PA).

As used herein the expression "polypeptide" encompasses proteins or epitopic fragments thereof.

Suitable polypeptides are sub-unit vaccines.

- In a preferred embodiment, the formulation of the invention  
5 comprises a biologically active agent which is capable of  
generating a protective immune response against *Yersinia pestis*.  
The agent is suitably a sub-unit vaccine, for example V antigen  
of *Y. pestis* or an immunologically active fragment thereof or a  
variant of these, or the F1 antigen of *Y. pestis* or an  
10 immunologically active fragment thereof or a variant of these,  
or a combination of these. In particular as described in WO  
96/28551, preferred vaccine comprises a combination of the F1  
and V antigens.
- 15 As used herein, the term "fragment" refers to a portion of the  
basic sequence that includes at least one antigenic determinant.  
These may be deletion mutants. One or more epitopic region of  
the sequence may be joined together.
- 20 The expression "variant" refers to sequences of nucleic acids  
that differ from the base sequence from which they are derived  
in that one or more amino acids within the sequence are  
substituted for other amino acids. Amino acid substitutions  
may be regarded as "conservative" where an amino acid is  
25 replaced with a different amino acid with broadly similar  
properties. Non-conservative substitutions are where amino  
acids are replaced with amino acids of a different type.  
Broadly speaking, fewer non-conservative substitutions will be  
possible without altering the biological activity of the  
30 polypeptide. Suitably variants will be at least 60% identical,  
preferably at least 75% identical, and more preferably at least  
90% identical to the base sequence. Identity in this case can be  
determined using available algorithms such as the widely used  
BLAST program.

The applicants have found that nebulization of PLA microspheres generates a respirable 'plume' of aerosolised particles, and this approach can be used to deliver immunogens to the respiratory tracts of experimental animals. Similar plumes  
5 could be produced using other forms of inhaler such as dry powder inhalers.

Microspheres used are suitably small enough to allow them to be administered to the deep lung using a conventional nebulizer or  
10 inhaler. For this purpose, microspheres will be less than 5 $\mu$ m average diameter, preferably less than 3 $\mu$ m average diameter, for instance from 0.5-3 $\mu$ m, or more preferably from 1-3 $\mu$ m and most preferably with an average diameter of between 1 and 1.5 $\mu$ m.

15 Suitably 0% of microspheres have an aerodynamic diameter above 10 $\mu$ m. More suitably, 0% of microspheres have an aerodynamic diameter above 9 $\mu$ m, and preferably 0% of microspheres have an aerodynamic diameter above 6 $\mu$ m.

20 Suitably, at least 90%, and preferably at least 95% of the microspheres in the formulation have an aerodynamic diameter of less than 5 $\mu$ m, preferably with at least 80% of particles having a mean mass aerodynamic diameter of less than 3  $\mu$ m.

25 By using microspheres of this size, efficient delivery of reagent into the deep lung is achieved. This is important in the delivery of reagents of this type as it is essential to achieve the highest concentrations of reagent, which can feasibly and safely be delivered in order to achieve the  
30 protective immune response.

Microspheres are suitably biodegradable and are produced from polymeric material. The polymeric material is suitably a biodegradable polymer other than a lipid, and in particular a  
35 biodegradable polyester. A particularly suitable polymer for

use in the preparation of microcapsules is Poly-lactide (PL) although other polymers such as poly(lactide-co-glycolide) PLGA may also be employed.

- 5 The microspheres may optionally further comprise agents which stabilise emulsions such as polyvinylalcohol (PVA), dipalmitoyl-phosphatidylcholine (DPPC), or methyl cellulose, and preferably polyvinylalcohol.
- 10 Suitably the non-living reagent is encapsulated within the microspheres (microcapsules). This again ensures the a high dose of the reagent is delivered to the lung which is important if a protective immune response is to be generated.
- 15 Microcapsules are suitably prepared using conventional methods such as the double emulsion/solvent evaporation method, as described for example by Beck et al., 1979, Fertility and Sterility, 31:545-551.
- 20 The encapsulation is suitably achieved using a double emulsion solvent evaporation method, in which a first emulsion is formed with the non-living reagent, and the structural polymer, mixing this with an aqueous phase (suitably without structural polymer) to form a secondary emulsion, evaporating solvent and isolating
- 25 small microspheres. In particular, the pharmaceutically active ingredient is dissolved or suspended in an aqueous solution, which optionally includes an emulsifier such as PVA. The emulsifier, where present is suitably included at low concentrations for example of less than 5%w/v. This solution or
- 30 suspension is then mixed with a solution of the high molecular weight structural polymer in an organic solvent such as dichloromethane. A primary emulsion is then formed, in particular by sonication of the mixture. The primary emulsion is then added to a secondary aqueous phase, which preferably
- 35 includes an emulsifier with vigorous stirring. Solvent is then preferably evaporated, conveniently at room temperature.

Microspheres can then be recovered, for example by centrifugation followed by lyophilisation.

The formulations of the invention may comprise microspheres per se which are optionally preserved, for example by lyophilisation, or the microspheres may be combined with a pharmaceutically acceptable carrier or excipient. Examples of suitable carriers include solid carriers as is understood in the art for use in nebulizers.

In a particularly preferred embodiment, the formulation further comprises the non-living reagent in free form. The ratio of the amounts of the free reagent to the reagent associated with the microspheres used in the composition may vary depending upon the particular agents being employed. Suitably the ratio of the free reagent to the reagent contained in the microspheres is in the range of from 1:20 to 2:1 and preferably at about 1:10.

The formulation of the invention may further comprise an adjuvant in order to enhance the immune response to the biologically active material administered. Suitable adjuvants include pharmaceutically acceptable adjuvants such as Freund's incomplete adjuvant, alhydrogel, aluminium compounds and, preferably adjuvants which are known to up-regulate mucosal responses such as CTB, the non-toxic pentameric B subunit of cholera toxin (CT) or mutant heat-labile toxin (mLT) of *E.coli*. They may also include immunomodulators such as cytokines and CpG motifs.

Other adjuvant types are described in International Patent Application Nos. WO00/56282, WO00/56362 and WO00/56361.

Suitably the formulations are in unit dosage form. This will vary depending upon the nature of the active agent being employed, the nature of the patient, the condition being treated



Further according to the invention there is provided a method of producing a protective immune response in a mammal in need thereof, said method comprising administering to the lung of  
5 said mammal, a protective amount of an aerosol formulation as described above.

The invention will now be particularly described by way of example with reference to the accompanying diagrammatic drawings  
10 in which:

Figure 1 is a micrograph showing the morphology of microspheres prior to (A) and after (B) nebulization;

15 Figure 2 is a graph showing serum anti-V IgG endpoint titre in 6 BALB/c mice exposed to aerosolised microspheres containing recombinant *Yersinia pestis* V antigen; and

Figure 3 illustrates the survival of mice, previously exposed to aerosolised microspheres containing rV antigen, after  
20 subcutaneous injection of 6.5 MLDs *Y. pestis*;

Figure 4 is a fluorescence micrograph of lung taken 24 hours following exposure of mice to aerosolised microspheres loaded  
25 with FITC-BSA; and

Figure 5 is a fluorescence micrograph of lung lymph node taken 24 hours following exposure of mice to aerosolised microspheres loaded with FITC-BSA.

30

#### Example 1

Poly-lactide (resomer L210) microspheres containing either BSA or recombinant V antigen from *Y. pestis* were fabricated using a modified double-emulsion solvent evaporation process. PLA, sold  
35 under the trade name Resomer L210, is a linear crystalline homopolymer with an inherent viscosity of approximately 3.6.

and other clinical factors. In general however, the formulations of the invention will comprise approximately 0.5 to 10 w/w of non-living reagent.

5 Exposed animals, in this case, mice, respond with a humoral response. It has also been found that experimental animals can be protected by this treatment from a lethal challenge with a pathogen such as the plague causing bacteria (*Yersinia. pestis*) by exposure to aerosolised microspheres containing recombinant V  
10 antigen. The applicants are therefore the first to demonstrate the successful aerogenic immunisation using non-living vaccines.

Dosages of the formulations of the invention will depend upon various factors such as the the nature of the patient, the  
15 antigen used etc. and will be determined according to known clinical practice.

It has been found that in a particularly preferred embodiment, each administration of microsphere preparation to a mouse  
20 contains from 1-100µg, suitably from 30-50µg and most preferably about 40µg of each of said antigens. Preferably the dosage to humans and mammals would be of the same order in terms of mg/Kg.

According to a further aspect of the invention, there is  
25 provided a nebulizer or inhaler comprising a formulation as described above.

Dry powder inhalers may be particularly useful in the context of the invention as dry vaccine formulations, which would be used  
30 therein, are stable at ambient temperatures.

In yet a further aspect, the invention provides the use of microspheres comprising a non-living reagent that produces a protective immune response in a mammal to whom it is  
35 administered, in the preparation of a vaccine for administration as an aerosol.

The polymer was used at a concentration of 1.38%w/v in dichloromethane (10ml). An aqueous solution (0.5ml) containing the antigen of interest (about 4mg) was then added and the mixture stirred at high speed to generate an emulsion. This emulsion was then added to a second aqueous phase and mixed together at high speed.

The solvent was then evaporated to leave an aqueous suspension of antigen-loaded microspheres.

Particles were aerosolised using a Sidestream® nebulizer. An aerosol particle sizer was used to analyse size characteristics. Samples were collected using a three stage liquid impinger and analysed using scanning electron microscopy, SDS PAGE and western blotting procedures.

6 female BALB/c mice were exposed to a stream of aerosolised microspheres in a head only exposure line. 77mg of rV loaded microspheres were suspended in 17 ml of free V (at 0.4mg ml<sup>-1</sup> in distilled water). Mice were exposed to the aerosolised microspheres for three ten minute runs, during which time approximately 3 ml of particle suspension was nebulized each run. The was repeated on days 0, 21 and 107 of the experiment and sera analysed for the presence of anti-V IgG using an indirect ELISA. In order to assess the extent of protection afforded by inhalation of the V loaded microspheres, mice were injected subcutaneously with 6.3MLDs *Y. pestis* (GB strain) on day 136 of the experiment.

### Results and Discussion

Microspheres had a loading of 3.8% w/w (BSA) and 3.3% w/w (rV). Following aerosolisation the BSA loaded particles had a mass median aerodynamic diameter of 1.3± 1.4µm, with 93% of the particles under 3µm. Following nebulization, particles retained their morphology/topography (Figure 1) and contained antigenic material as detected by Western Blotting.

Although there was some inter-animal variation in the serum antibody response to aerosolised *Y. pestis* rV antigen, all 6 mice seroconverted after three immunising doses (Figure 2). Two  
5 of the six mice responded with antibody titres that were of significant magnitude to confer protection from injected challenge with plague causing bacteria (Figure 3).

#### Example 2

#### 10 Delivery of microencapsulated antigen to the lung and lung lymph node by aerosolisation

Poly-lactide (resomer L210, Alfa chemicals UK) microspheres, containing FITC-BSA were fabricated using a modified double-  
15 emulsion solvent evaporation process. Particles were aerosolised using a Sidestream® nebulizer (Profile, UK). Female BALB/c mice were exposed to the aerosolised microspheres in a head only exposure chamber. 24 hours following exposure mice were killed and their lungs and lung's lymph nodes were  
20 extracted. Frozen sections were obtained from the extracted tissues using a cryostat. Frozen sections were examined for the presence of FITC-BSA loaded microspheres using a fluorescence microscope and the results for the lung and lung lymph nodes are shown in Figures 4 and 5 respectively.

25

The visualisation of punctate fluorescent material in the sections indicated the presnce of FITC-BSA loaded microspheres in the lung and lymph nodes. These data support the tenet that microspheres can reach enter the lower respiratory tract  
30 following nebulization. Furthermore, these data indicate that microspheres may be translocated from the lungs to the draining lymph nodes, following nebulization.

35

## Claims

1. An aerosol formulation comprising a biodegradable  
microsphere of average diameter of from 0.5 to 5µm comprising a  
5 non-living reagent that produces a protective immune response in  
a mammal to whom it is administered.
2. A formulation according to claim 1 wherein the said non-  
living reagent is antigenic polypeptide or a nucleic acid  
10 sequences which may encode such a polypeptide.
3. A formulation according to claim 2 wherein the said non-  
living reagent is a sub-unit vaccine.
- 15 4. A formulation according to any one of the preceding claims  
wherein the said non-living reagent is diptheria toxoid, tetanus  
toxoid, *Botulinum* toxin FHC, *Bacillus anthracis* protective  
antigen (PA) or a polypeptide which is capable of generating a  
protective immune response against *Yersinia pestis*.  
20
5. A formulation according to claim 4 wherein the non-living  
reagent is the V antigen of *Y. pestis* or an immunologically  
active fragment thereof or a variant of these, or the F1 antigen  
of *Y. pestis* or an immunologically active fragment thereof or a  
25 variant of these, or a combination of these.
6. A formulation according to any one of the preceding claims  
wherein the microspheres have an average diameter of less than  
3µm.  
30
7. A formulation according to claim 6 wherein the  
microcapsules have an average diameter of between 1 and 1.5µm.
8. A formulation according to any one of the preceding claims  
35 wherein the microsphere comprise a biodegradable polyester.

9. A formulation according to claim 8 wherein the polyester comprisescomprise Poly-lactide (PL).

10. A formulation according to any one of the preceding claims  
5 wherein the microcapsules are lyophilised.

11. A formulation according to any one of the preceding claims wherein the non-living reagent is encapsulated within the microspheres.

10

12. A formulation according to any one of the preceding claims which further comprises the non-living reagent in free form.

13. A formulation according to claim 12 wherein the ratio of  
15 the amounts of the free reagent to the reagent associated with the microspheres is in the range of from 1:20 to 2:1.

14. A formulation according to any one of the preceding claims in unit dosage form.

20

15. A nebulizer or inhaler comprising a formulation according to any one of the preceding claims.


16. The use of biodegradable microspheres having an average  
25 diameter of from 0.5 to 5µm and comprising a non-living reagent that produces a protective immune response in a mammal to whom it is administered, in the preparation of a vaccine for administration as an aerosol.

30 17. A method of producing a protective immune response in a mammal in need thereof, said method comprising administering to the lung of said mammal, a protective amount of an aerosol formulation according to any one of claims 1 to 14.


1/3

Figure 1

A



B



JC20 Rec'd PCT/PTO 1 5 JUL 2005

**THIS PAGE BLANK** (USPTO)



2/3

Figure 2





Figure 3



IC20 Rec'd P&A/10 1 5 JUL 2005

**THIS PAGE BLANK (USPTO)**

3/3

Figure 4





Figure 5



JC20 Rec'd PCT/PTO 1 5 JUL 2005

**THIS PAGE BLANK** (USPTO)

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB2004/000104

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 7 A61K9/72 A61K39/39				
According to International Patent Classification (IPC) or to both national classification and IPC				
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE				
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>				
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	WO 02/43705 A (UNIV FLORIDA) 6 June 2002 (2002-06-06)  page 3, line 35 - page 4, line 14 page 4, line 17 - line 39 page 5, line 11 - line 27 page 11, line 45 - page 12, line 38 page 13, line 8 - line 21 page 13, line 25 - page 14, line 6 examples claims  ----- -/--	1,2, 6-11, 14-17		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.				
<b>* Special categories of cited documents :</b> <table border="0"> <tr> <td style="vertical-align: top;"> <b>*A*</b> document defining the general state of the art which is not considered to be of particular relevance  <b>*E*</b> earlier document but published on or after the international filing date  <b>*L*</b> document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  <b>*O*</b> document referring to an oral disclosure, use, exhibition or other means  <b>*P*</b> document published prior to the international filing date but later than the priority date claimed               </td> <td style="vertical-align: top;"> <b>*T*</b> later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  <b>*X*</b> document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  <b>*Y*</b> document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  <b>*Z*</b> document member of the same patent family               </td> </tr> </table>			<b>*A*</b> document defining the general state of the art which is not considered to be of particular relevance <b>*E*</b> earlier document but published on or after the international filing date <b>*L*</b> document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) <b>*O*</b> document referring to an oral disclosure, use, exhibition or other means <b>*P*</b> document published prior to the international filing date but later than the priority date claimed	<b>*T*</b> later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention <b>*X*</b> document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone <b>*Y*</b> document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. <b>*Z*</b> document member of the same patent family
<b>*A*</b> document defining the general state of the art which is not considered to be of particular relevance <b>*E*</b> earlier document but published on or after the international filing date <b>*L*</b> document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) <b>*O*</b> document referring to an oral disclosure, use, exhibition or other means <b>*P*</b> document published prior to the international filing date but later than the priority date claimed	<b>*T*</b> later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention <b>*X*</b> document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone <b>*Y*</b> document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. <b>*Z*</b> document member of the same patent family			
Date of the actual completion of the international search  2 June 2004		Date of mailing of the international search report  16/06/2004		
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer  Epskamp, S		

# INTERNATIONAL SEARCH REPORT

national Application No

.CT/GB2004/000104

**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EYLES J E ET AL: "Protection studies following bronchopulmonary and intramuscular immunisation with Yersinia pestis F1 and V subunit vaccines coencapsulated in biodegradable microspheres: a comparison of efficacy" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 18, no. 28, August 2000 (2000-08), pages 3266-3271, XP004205869 ISSN: 0264-410X	1-11, 14-17
Y	abstract paragraphs '02.2!', '02.3! paragraph '0004!	1-17
X	EYLES J E ET AL: "Analysis of local and systemic immunological responses after intra-tracheal, intra-nasal and intra-muscular administration of microsphere co-encapsulated Yersinia pestis sub-unit vaccines" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 16, no. 20, 1 December 1998 (1998-12-01), pages 2000-2009, XP004138449 ISSN: 0264-410X	1-11, 14-17
Y	abstract page 2001, right-hand column, last paragraph - page 2002, left-hand column, paragraph 1 page 2002, right-hand column, last paragraph page 2003, right-hand column, paragraph 5 page 2008, right-hand column	1-17
Y	WO 01/70200 A (SECR DEFENCE ; ALPAR HAZIRE OYA (GB); EYLES JAMES EDWARD (GB); WILLIAM) 27 September 2001 (2001-09-27) page 4, line 14 - page 5, line 3 examples claims	1-17
X	WILLIAMSON E D ET AL: "Local and systemic immune response to a microencapsulated sub-unit vaccine for plague" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 14, no. 17, 1 December 1996 (1996-12-01), pages 1613-1619, XP004016821 ISSN: 0264-410X abstract page 1614, left-hand column, paragraph 4 - right-hand column, paragraph 4	1-11, 14-17
	----- -/--	

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB2004/000104

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>EYLES J E ET AL: "Microsphere translocation and immunopotential in systemic tissues following intranasal administration"</p> <p>VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 19, no. 32, 14 September 2001 (2001-09-14), pages 4732-4742, XP004303168</p> <p>ISSN: 0264-410X</p> <p>abstract</p> <p>paragraph '02.4!</p> <p>-----</p>	<p>1-11, 14-17</p>

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB2004/000104

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0243705	A	06-06-2002	AU 3060902 A	11-06-2002
			US 2002159954 A1	31-10-2002
			WO 0243705 A2	06-06-2002
WO 0170200	A	27-09-2001	AU 3940701 A	03-10-2001
			CA 2399695 A1	27-09-2001
			EP 1265598 A1	18-12-2002
			WO 0170200 A1	27-09-2001
			JP 2003527413 T	16-09-2003



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☒ FADED TEXT OR DRAWING

☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**